 model updat rais pt
messag merck present posit data phase trial lung
cancer yesterday see note morn due better expect
readout increas revenu estim keytruda lung cancer
rais price target
rais price target base posit result
present earlier today made modest adjust model base
posit readout merck phase trial evalu keytruda
nsclc result posit readout expect present data ad
label shortli ultim increas keytruda sale year well merck
posit lung cancer market thu increas keytruda sale estim
approxim model keytruda sale
adjust ep estim fy increas revenu
valuat risk
valuat valuat methodolog base dcf analysi believ best
captur overal valu busi merck dcf take present
valu cash flow within forecast window thereaft wind exist
product busi includ risk-adjust contribut pipelin asset use
unchang lt growth rate wacc translat dcf valu
price target chang pt result increas keytruda revenu
estim follow posit readout current trade
ep estim estim revenu approxim
risk risk rate valuat includ setback key pipelin asset high
competit market competitor bristol-my roch
rhhbi similar compound ident therapeut area hcv competit
increas spend clinic trial particularli line extens keytruda
page analyst certif import disclosur
million except per-shar figur
equiti loss incom affili
net incom attribut non-controlling interest
page analyst certif import disclosur
